Lucid Diagnostics Inc.

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company focused on preventing esophageal adenocarcinoma in patients with gastroesophageal reflux disease. Its core products include EsoCheck, a noninvasive swallowable balloon capsule catheter used for targeted esophageal cell sampling, and EsoGuard, a targeted next-generation sequencing DNA test designed to detect esophageal precancer. The company markets its diagnostic products to primary care and gastroenterology physicians, self-insured employers, unions, and healthcare systems, while also providing testing through commercial health network arrangements and a direct-to-consumer telemedicine program.

The company operates its own clinical laboratory in Lake Forest, California, along with dedicated physical Lucid Test Centers and satellite collection sites in physician offices. EsoCheck has received regulatory clearance in the United States and CE Mark certification in Europe, and cell collection devices are produced through third-party manufacturing partners. The text does not disclose the location of the corporate headquarters.

Summary of the business section of Lucid Diagnostics's latest annual report, written by StockData.

“As of March 23, 2026 we have 82 employees (all of whom are full-time employees), inclusive of our executive officers – our Chairman of the Board of Directors and Chief Executive Officer (“CEO”), our President and Chief Operating Officer (“President” or “COO”), our Chief Financial Officer (“CFO”), our General Counsel and Secretary (“General”